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ABSTRACT
This paper reports the MEPS-HPLC-DAD method for the simultaneous determination of 12 azole drugs
(bifonazole, butoconazole, clotrimazole, econazole, itraconazole, ketoconazole, miconazole, posaconazole,
ravuconazole, terconazole, tioconazole and voriconazole) administered to treat different systemic and top-
ical fungal infections, in biological samples. Azole drugs separation was performed in 36min. The analytical
method was validated in the ranges as follows: 0.02–5lg mL1 for ravuconazole; 0.2–5lg mL1 for terco-
nazole; 0.05–5lg mL1 for the other compounds. Human plasma and urine were used as biological sam-
ples during the analysis, while benzyl-4-hydroxybenzoate was used as an internal standard. The precision
(RSD%) and trueness (Bias%) values fulfill with International Guidelines requirements. To the best of our
knowledge, this is the first HPLC-DAD procedure coupled to MEPS, which provides the simultaneous ana-
lysis of 12 azole drugs, available in the market, in human plasma and urine. Moreover, the method was
successfully applied for the quantitative determination of two model drugs (itraconazole and miconazole)
after oral administration in real samples.
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Introduction
Imidazole drugs are organic water-soluble compounds showing a
diazole aromatic heterocycle with non-adjacent nitrogen atoms,
which has two equivalent tautomeric forms due to the presence
of two nitrogen atoms in the backbone structure. The imidazole
ring is widely present in various natural products, e.g. alkaloids,
histamine, histidine, purine, which share the same 1,3-C3N2 basic
ring with different substituents on the side chains. The imidazole
also forms the key building block of different drugs possessing
several biological activities, such as antibacterial, anticancer, anti-
fungal and analgesic1.
Triazoles represent another group of azole derivatives with a
broader antifungal spectrum and safer profile than imidazoles2.
The triazole antifungal drugs include fluconazole, isavuconazole,
itraconazole, posaconazole, pramiconazole, ravuconazole and vori-
conazole. Azoles (both imidazoles and triazoles) represent the
active principle ingredient (API) of different drugs, which are topic-
ally or systemically administered as creams, shampoos, powders,
tablets and capsules to treat fungal infections3. Bifonazole, butoco-
nazole, clotrimazole, econazole, ketoconazole, miconazole, tiocona-
zole and terconazole are commonly formulated as creams and
powders, whereas itraconazole, ketoconazole, posaconazole and
voriconazole are formulated as tablets and capsules.
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Pursuing our interest in the search and development of anti-
fungal drugs4–10, the aim of this project was the quantification of
azole derivatives, currently available in the market, in real samples
through innovative microextraction techniques.
The analysis of the antifungal drugs in biological samples, e.g.
plasma and urine, was usually carried out using high-performance
liquid chromatography (HPLC) coupled to fluorimetric
detector11–13, UV/Vis14–18, mass spectrometry (HPLC-MS)19, tandem
mass spectrometry (HPLC-MS/MS)20–22 and other highly hyphen-
ated instrument configurations23. HPLC-diode array (DAD) or UV/
Vis detectors are also used to quantify azoles in pharmaceutical
products24–26. A C18, C8 or C6-phenyl stationary phase and aceto-
nitrile, as mobile phase, are often used to set up a rugged and
routinary analytical method, which can be scaled up for the indus-
trial quality control procedures.
Although several analytical methods were developed to quanti-
tate azole drugs in pharmaceutical compounds, no HPLC-DAD
method coupled to microextraction by packed sorbent (MEPS) tech-
nique is actually available to analyze simultaneously several azole
derivatives in biological samples. Indeed, few works showed the
separation of a limited number of triazoles, e.g. posaconazole and
voriconazole15,27, or fluconazole, itraconazole, voriconazole, posa-
conazole23, or fluconazole, itraconazole, voriconazole, posaconazole
and ketoconazole28, or ketoconazole, tioconazole, econazole, mico-
nazole and itraconazole29 from biological samples. Up to date, a
proper method for the simultaneous quantification of all the deriva-
tives in Figure 1, suitable for clinical applications, was not reported.
The clean-up and extraction procedure can decrease the
recovery of compounds, which show different physical–chemical
properties and limit the optimization of the method for multiple
drugs determination. The liquid–liquid extraction (LLE) with
organic solvents15,27,29 and protein precipitation are widely used
to extract drugs from biological samples30; unfortunately, they
often show suitable performances on a limited number of drugs
as demonstrated by the low quantitative recovery of bifonazole,
butoconazole, ravuconazole and terconazole in the biological
samples. To improve the extraction procedure, the solid phase
extraction (SPE) procedure was proposed28. In the herein
reported study, the SPE extraction was carried out testing differ-
ent stationary phases, such as Oasis HLB, Strata-X and Sep-Pak.
The SPE sorbents were conditioned according to the instructions
from the manufacturer and to Gordien et al.’s protocol28. The
SPE extraction increased drugs recovery (>60%). Unfortunately,
for this procedure, a large amount of samples, buffers and
organic solvents was required. Furthermore, the SPE procedure
could be time-consuming and samples must be dried to reduce
volume before HPLC analysis to achieve better LOQ values and
to improve the signal-to-noise ratio. To overcome these draw-
backs, MEPS microextraction technique was tested to optimize
the recovery and the time of analysis, as previously observed in
other works31–33, and then applied to biological samples. In fact,
this procedure increased the recovery of samples and decreased
both the time of analysis and the use of organic solvents com-
pared with SPE.
The obtained MEPS-HPLC-DAD protocol can provide several
advantages for the concurrent extraction and analysis of azole
derivatives in biological samples compared with other complex
methods. Furthermore, the availability of a procedure for the
determination of several analytes could be useful for clinical appli-
cations. The reported method showed comparable (or better) ana-
lytical performances to the others reported in the literature (see
section Comparisons with existing methods).
Materials and methods
Chemicals, solvents and devices
Bifonazole, butoconazole, clotrimazole, econazole, itraconazole,
ketoconazole, miconazole, posaconazole, ravuconazole, tercona-
zole, tioconazole, voriconazole and benzyl-4-hydroxybenzoate
Figure 1. Chemical structures of the selected 12 azoles.
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(Internal Standard, IS) (>98% purity grade), sodium phosphate
monobasic and sodium phosphate dibasic (>99% purity grade),
phosphoric acid (90% purity grade) and trichloroacetic acid (>99%
purity grade) were purchased from Sigma-Aldrich (Milan, Italy).
The commercial drugs were obtained from a local Pharmacy
after medical prescription. Both HPLC-grade Acetonitrile (AcN) and
methanol (MeOH) were supplied by Carlo Erba (Milan, Italy) and
were used without further purification. The water for HPLC analysis
was generated by using a Millipore Milli-Q Plus water treatment
system (Millipore Bedford Corp., Bedford, MA). Oasis HLB (1mL,
30mg) and Sep-Pak (1mL, 50mg) were obtained from Waters
(Milford, MA), while Strata-X (1mL, 30mg) was purchased from
Phenomenex (Torrance, CA). MEPS device (syringe) and replace-
ment needle with C18 stationary phase were purchased from SGE
Analytical Science (Melbourne, Australia).
Stock solution, calibration curve and quality control analysis
The 12 stock solutions of chemical standards were made at the con-
centration of 1mg mL1 in the mobile phase. The combined work-
ing solutions (concentration range: 0.5–50lg mL1) were carried
out by dilution of a mixed solution. The matrix-matched calibration
standards and quality control samples (QCs) were carried out in bio-
logical matrices (plasma and urine) as reported in Section “Plasma
and urine samples preparation”. The resulting samples were
injected in HPLC-DAD instrument after MEPS extraction.
Plasma and urine collection and storage
Plasma and urine samples were collected from healthy volunteers,
which were informed on the experimental procedures and the
nature of the study, and gave a written consent. No medications
were administered to healthy volunteers before the experiments.
The study was conducted in line with Good Clinical Practice guide-
lines and with the ethical principles laid down in the latest version
of the Declaration of Helsinki. The plasma samples were collected
into heparinized tubes, while urine samples were collected into
sterilized containers. All samples were stored at 20 C before the
analysis.
Plasma and urine samples preparation
About 170 lL of human blank plasma or urine were mixed with
20 lL of analyte working solutions and 10lL of IS (1lg mL1) and
vortexed for 3min (15% v:v of matrix modification for calibration
and QC samples and 5% v:v of matrix modification for real
samples).
Biological samples were diluted using trichloroacetic acid (TCA)
(20mg mL1) in 1:0.5 (v:v) ratio31–33, centrifuged (12,000 g for
10min) and extracted by MEPS apparatus. The TCA treatment was
carried out to denature the biological proteins, to hydrolyze the
drug-protein binding and to reduce the sample density34 (widely
used in biochemistry also for the precipitation of macromolecules,
such as proteins, DNA and RNA). This acid was chosen to provide
greater stability of the selected analytes in acidic conditions with
respect to the reported harsh conditions (1.0M perchloric acid)17.
The supernatant was loaded in the MEPS, cleaned using water
(200 lL), eluted and directly injected into the HPLC-DAD using
methanol (20 lL). The analysis showed the presence of interfer-
ence peaks, but a suitable recovery of drugs in terms of signal-to-
noise ratio and peak areas compared with SPE treated samples.
The off-line extraction procedure was optimized as follows: (i)
conditioning of sorbent with 3 150lL of methanol and 3 150lL
of phosphate buffer (40mM, pH 2.5); (ii) loading of plasma samples
diluted 1:0.5 (v:v) with TCA (20mg mL1) (8 150lL) or urine sam-
ples diluted 1:0.5 (v:v) with TCA (20mg mL1) (8 200lL); (iii)
washing with 1 200lL of phosphate buffer (40mM, pH 2.5) and
methanol (90:10, v:v); (iv) elution of samples with 8 25lL
of methanol in a single vial by using an average flow rate of
10lL s1, and then directly injected into the HPLC-DAD system.
This optimized procedure is reported graphically in Figure 2.
Apparatus and chromatographic conditions
Analyses were performed using an HPLC Waters liquid chromatog-
raphy (model 600 solvent pump, 2996 DAD, Waters Corporation,
Milford, MA). Mobile phase was directly on-line degassed by using
a Biotech 4CH DEGASI Compact (Biotech Inc., Onsala, Sweden).
Figure 2. Schematic illustration of the optimized MEPS extraction procedure.
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Empower v0.2 Software (Waters Spa, Milford, MA) was used to col-
lect and analyze the data.
Two different columns were used to optimize the chromato-
graphic conditions: Luna C18 (250 4.6mm, 5lm particle size,
Phenomenex, Torrance, CA) and Discovery C8 column
(250 4.6mm, 5 lm particle size, Supelco, Milan, Italy). The Luna
C18 packing column connected to a Security Guard column
(4.0 3.0mm, 5 lm particle size; Phenomenex, Torrance, CA) was
finally used to separate 12 azole drugs and IS. The columns were
thermostated at 25 C (± 1 C) using a Jetstream2 Plus column
oven during the analysis.
The maximum wavelength of 210 nm24 was used to obtain the
best signal-to-noise ratio during HPLC-DAD analysis and the max-
imum values of LODs, LOQs, although these compounds can be
detected at 250 nm25, 243 nm and 220 nm35. These secondary
maximum wavelengths were used to further identify the azole
drugs during the analysis (Supplementary material, Section S1 for
analytes and IS UV/Vis spectra and Section S2 for system suitability
test).
The HPLC system was optimized to set-up the better signal-to-
noise ratio of drugs in a single chromatographic analysis, the best
peak shape, an appropriate run-time and the better peak reso-
lution. First, the analyses were performed in isocratic conditions
using Luna C18 or Discovery C8 column as previously
reported16,19,27, in different mobile phases, made up from organic
solvents and buffers with increasing ionic strength (15mM, 30mM,
40mM and 50mM), in different temperature (25 C, 35 C and
40 C) and pH (2.5, 3.0 and 5.5) conditions. The flow rate was
always kept at 1.0mL min1 during the analysis.
Results showed that the retention times decreased by increas-
ing the buffer ionic strength from 15mM to 30mM phosphate
buffer (pH 2.5). The retention times of drugs were also reduced by
increasing column temperature from 25 C to 40 C; unfortunately,
a broader shape of peaks occurred, probably related to an
increased mass transfer kinetics and a corresponding reduction in
terms of resolution and peak symmetry. Similar results were
obtained by increasing pH value from 2.5 to 5.5. Symmetric peaks
were obtained both at 40mM and 50mM of phosphate buffer (pH
2.5). A suitable resolution was obtained using Luna C18, phosphate
buffer (40mM, pH 2.5) as solvent A, acetonitrile as solvent B, iso-
cratic conditions (58:42, v:v) at 25 C.
This condition provided the simultaneous analysis of the 12
azole drugs, but the major drawback was the high-retention times
of ravuconazole (61.8min) and itraconazole (67.2min). The long-
retention times of these two drugs in addition to the run time
analysis (>68min) and the low signal-to-noise ratio hampered the
isocratic condition preliminary performed. For these reasons, differ-
ent gradient elution modes, at the same conditions of ionic
strength, pH and temperature, were tested to decrease the run
time and improve the signal-to-noise ratio. The optimized gradient
elution was 0–16min, 42% B; 16–18min, from 42% to 70% B, lin-
ear; 18–21min, from 70% to 80% B, linear; 21–28min, 80% B;
28–36min, 42% B. This gradient allowed separating simultaneously
these drugs and IS without any overlapping and interferences dur-
ing the analysis (Figure 3). By using the optimized separation con-
ditions, a baseline resolution for different drugs and IS was carried
out by 36min and the resulting retention times are reported in
Tables 1 and 2 (see also Supplementary material, Section S2 for
System Suitability Test (SST) separation).
Summarizing, the optimized HPLC elution comprises mobile
phase composed by phosphate buffer (40mM, pH 2.5), as solvent
A, and AcN, as solvent B, at a flow rate of 1.0mL min1, and the
following gradient elution: 0–16min, 42% B; 16–18min, from 42%
to 70% B, linear; 18–21min, from 70% to 80% B, linear; 21–28min,
80% B; 28–36min, 42% B.
Method validation
The validation of analytical method was carried out according to
the International Guidelines36–38 in order to check LODs, LOQs, lin-
earity, intra- and inter-day trueness and precision, selectivity,
recovery, stability and parallelism test of different drugs in plasma
and urine samples.
The LOQ of the method was defined as the concentration of
the lowest standard on the calibration curve for which (a) the ana-
lyte peak was identifiable and discrete, (b) the analyte response
was at least 10 times the response of the blank sample and (c) the
analyte response was reproducible with a precision less than 20%
and trueness better of 80–120%. The LOD was estimated at a sig-
nal-to-noise ratio of 3:1 by injecting a series of samples with
known concentrations. Precision and trueness studies were carried
out at the LOQ and at three QC concentration levels by injecting
six different preparations of the analytes and calculating the RSD%
and Bias% of the back-calculated concentrations. Calibration
curves were calculated by analyzing six-times these eight non-zero
concentration standards (0.02, 0.05, 0.10, 0.20, 0.50, 0.80, 2.00 and
5.00 lg mL1, for ravuconazole; 0.20, 0.30, 0.50, 0.80, 1.50, 2.00,
3.00 and 5.00lg mL1 for terconazole; 0.05, 0.10, 0.20, 0.30, 0.50,
0.80, 2.00 and 5.00 lg mL1, for all other azole drugs) prepared in
freshly spiked plasma (and urine).
Concentrations of the QCs and unknown samples were calcu-
lated by interpolating their analyte peak area/Internal Standard
area ratio on the calibration curve. Selectivity was tested by ana-
lyzing, under optimized chromatographic conditions, six blank
plasma and six urine samples from different sources, and by com-
paring them with spiked ones at a concentration close to the
LOQ.
Results and discussion
Optimization of MEPS extraction procedure
Up to date MEPS applications cover a large variety of organic
compounds due to a great availability of sorbents (C2, C8, C18, C8-
SCX, SCX, SAX, silica and molecularly imprinted polymers). For the
herein considered analytes and for their chemical structures and a
wide range of log Kow values (ranging from 1.0 for voriconazole to
6.70 of butoconazole), the C18 type could represent a valid starting
point for extraction process optimization. The MEPS optimization
was performed using the blank samples (plasma and urine) spiked
with 0.15lg mL1 of different azole drugs. Using these samples,
the different parameters that could affect the extraction process
were evaluated.
Effect of sample volume
During extraction procedure optimization, especially by using
MEPS device, the sample volume covers an important role. In fact,
when complex matrices were analyzed, matrix components could
saturate the stationary phase, reducing the availability of func-
tional groups that can retain the analyte. Additionally, the use of
large sample volume could represent a limiting point for the
method applicability, particularly when biological matrices are con-
sidered. For these reasons and based on previously validated
MEPS procedures31–33, the whole extraction process was tested
and evaluated on a total sample volume of 150 lL for plasma and
200 lL for urine. Furthermore, in the MEPS procedure, the cycles
4 C. CAMPESTRE ET AL.
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number could also represent a critical point, due to the possible
pre-concentration enhancement particularly during sample loading
and sample elution. The effects of cycles number on process effi-
ciency for the different analytes are reported in Figure 4.
Effect of type of washing solvent and organic solvent percentage
To optimize the MEPS extraction, two different washing solvent
systems were tested: (i) methanol and phosphate buffer (pH 2.5,
40mM) at the ratios of 5:95 and 10:90 (v:v), (ii) methanol and
Figure 3. Chromatograms obtained after the extraction and analysis of 12 azoles and benzyl-4-hydroxybenzoate (IS) at the wavelength of 210 nm, respectively (up,
plasma sample and, down, urine sample: (a) blank sample, (b) blank sample spiked with 5lg mL1 of IS and (c) blank sample spiked with 5lg mL1 of IS and 4lg
mL1 of different drugs). 20lL of samples were injected during the analysis.
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water with HCl (0.1 N) at the ratios of 5:95 and 10:90 (v:v). The
obtained HPLC chromatograms showed that phosphate buffer (pH
2.5, 40mM) and methanol (90:10, v:v) (1 200 lL) were the best
performant solvent mixture, because it improved the analytes
extraction. The use of MEPS also decreased the time of sample
extraction up to 7min, plus further 10min to centrifuge samples.
Effect of number of draw–eject cycles
The instrument response, in terms of peak area, was optimized, by
performing multiple draw–eject extraction cycles and improving
the final clean-up of the device, in order also to increase the
device lifetime and the number of analyses by a single MEPS nee-
dle. The increase of draw–eject extraction cycles improved the
peak area for all analytes and reached a plateau after eight cycles
(Figure 4). Additionally, due to higher volumes available, for urine
samples, the procedure was performed with 200 lL instead of
150 lL. This last value represented the maximum volume that
could be obtained after protein precipitation with TCA.
Effect of type of eluting solvent and MEPS memory effects
The back extracting solvent volume is another critical parameter
that needs to be optimized in order to enhance the signal-to-noise
ratio. We tested different methanol volumes, 50, 75, 100, 150, 200
and 300 lL, and observed a signal improvement until 150 lL
before reaching a plateau. The methanol was used as an eluent to
obtain the maximum recovery of drugs and increased the area of
the peak for all compounds and IS.
The carry-over effect was evaluated using blank plasma (or
urine) injected after the analysis of fortified biological samples at
the upper limit of quantification (ULOQ, 5lg mL1) and no mem-
ory effect of analytical procedure was obtained during the
analysis.
Selectivity
The selectivity was performed using six blank biological samples
collected from different healthy volunteers, according to ICH
guidelines37. The blank samples showed neither area values over
20% of LOQ areas at the analyte retention times nor over 5% of IS
area at the drug retention time. This parameter was evaluated
using blank biological samples (plasma and urine) extracted by
MEPS device and analyzed with HPLC-DAD without any fortifica-
tion (a), after fortification with IS (b) or drugs and IS (c) (Figure 3).
Results demonstrated that the retention times of drugs were simi-
lar to those obtained for real samples and no interfering peaks
were detected during the analysis at 210 nm (Figure 3). The peak
before the retention time of ketoconazole was observed during
the analysis; however, the peak intensity and its retention did not
change in all chromatograms and did not affect the ketoconazole
quantification both in plasma and urine samples.
Effect of type of cleaning solvent on device lifetime
The cleaning solvent adopted in the optimized MEPS procedure is
pure methanol due to its high-elution capacity when the C18 sta-
tionary phase was used. The cleaning solvent choice was guided
Table 1. Mean linear calibration curve parameters performed by weighted-linear least-squares regression analysis of six independent eight non-zero concentration
points in plasma samples.
Linearity range
Slopea Intercepta
Determination Wavelength
Retention time (min)
Analyte (lg mL1) Mean Std. dev. Mean Std. dev. coefficient (r2) (nm) Mean Std. dev.
Ketoconazole 0.05–5 (0.017 lg mL1)b 0.07762 ±0.00485 0.00211 ±0.00019 0.9846 5.49 ±0.12
Terconazole 0.2–5 (0.070 lg mL1)b 0.1906 ±0.016364 0.01732 ±0.00207 0.9954 6.63 ±0.14
Voriconazole 0.05–5 (0.017 lg mL1)b 0.084313 ±0.00568 0.002999 ±0.002959 0.9917 9.94 ±0.13
Bifonazole 0.05–5 (0.017 lg mL1)b 0.376833 ±0.036575 0.01551 ±0.002246 0.9910 11.23 ±0.30
Clotrimazole 0.05–5 (0.017 lg mL1)b 0.1885 ±0.015932 0.01477 ±0.001127 0.9961 12.75 ±0.45
Tioconazole 0.05–5 (0.017 lg mL1)b 0.113067 ±0.014298 0.005134 ±0.000549 0.9908 210 14.19 ±0.34
Econazole 0.05–5 (0.017 lg mL1)b 0.129033 ±0.014347 0.003792 ±0.002456 0.9927 17.84 ±0.45
Butoconazole 0.05–5 (0.017 lg mL1)b 0.2452 ±0.022889 0.002835 ±0.004686 0.9925 22.64 ±1.84
Miconazole 0.05–5 (0.017 lg mL1)b 0.129033 ±0.020994 0.00083 ±0.003097 0.9922 23.22 ±0.12
Posaconazole 0.05–5 (0.017 lg mL1)b 0.1483 ±0.021392 0.00155 ±0.001385 0.9962 24.01 ±0.09
Ravuconazole 0.02–5 (0.007 lg mL1)b 0.032007 ±0.002906 0.002364 ±0.000659 0.9902 26.06 ±0.11
Itraconazole 0.05–5 (0.017 lg mL1)b 0.059923 ±0.011036 0.015467 ±0.002012 0.9924 28.31 ±0.10
aValues at 95% confidence intervals on the mean of six independent calibration curves.
bThe round brackets show the LOD values obtained from signal-to-noise ratio3; the slope and intercept of calibration curve are expressed in lg mL1.
Table 2. Mean linear calibration curve parameters performed by weighted-linear least-squares regression analysis of six independent eight non-zero concentration
points in urine samples.
Linearity range
Slopea Intercepta
Determination Wavelength
Retention time (min)
Analyte (lg mL1) Mean Std. dev. Mean Std. dev. coefficient (r2) (nm) Mean Std. dev.
Ketoconazole 0.05–5 (0.017 lg mL1)b 0.093827 ±0.005462 0.00211 ±0.00019 0.9877 5.49 ±0.12
Terconazole 0.2–5 (0.070 lg mL1)b 0.182667 ±0.019981 0.01732 ±0.00207 0.9938 6.63 ±0.14
Voriconazole 0.05–5 (0.017 lg mL1)b 0.070917 ±0.001684 0.002999 ±0.002959 0.9934 9.94 ±0.13
Bifonazole 0.05–5 (0.017 lg mL1)b 0.384167 ±0.082413 0.01551 ±0.002246 0.9958 11.23 ±0.30
Clotrimazole 0.05–5 (0.017 lg mL1)b 0.199733 ±0.044602 0.01477 ±0.001127 0.9970 12.75 ±0.45
Tioconazole 0.05–5 (0.017 lg mL1)b 0.1181 ±0.018455 0.005134 ±0.000549 0.9901 210 14.19 ±0.34
Econazole 0.05–5 (0.017 lg mL1)b 0.135533 ±0.0252 0.003792 ±0.002456 0.9870 17.84 ±0.45
Butoconazole 0.05–5 (0.017 lg mL1)b 0.232067 ±0.01817 0.002835 ±0.004686 0.9944 22.64 ±1.84
Miconazole 0.05–5 (0.017 lg mL1)b 0.134333 ±0.019278 0.00083 ±0.003097 0.9980 23.22 ±0.12
Posaconazole 0.05–5 (0.017 lg mL1)b 0.2156 ±0.020832 0.00155 ±0.001385 0.9951 24.01 ±0.09
Ravuconazole 0.02–5 (0.007 lg mL1)b 0.03004 ±0.003518 0.002364 ±0.000659 0.9969 26.06 ±0.11
Itraconazole 0.05–5 (0.017 lg mL1)b 0.098023 ±0.011686 0.015467 ±0.002012 0.9944 28.31 ±0.10
aValues at 95% confidence intervals on the mean of six independent calibration curves.
bThe round brackets show the LOD values obtained from signal-to-noise ratio3; the slope and intercept of calibration curve are expressed in lg mL1.
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also by the possible increase in device lifetime and reduction of
carry-over phenomena. For these reasons, the MEPS device was
washed using pure methanol (5 200 lL) before another extrac-
tion and no carry-over phenomena were observed. Furthermore,
the device could be re-used up to 70–90-folds, without any loss of
herein validated analytical performances, by using methanol.
Method validation
The matrix-matched calibration curves were calculated by analyz-
ing six-times the non-zero concentration standards made in freshly
spiked plasma or urine samples. The results were obtained by
plotting the analyte/IS area ratio for each level of quantification
versus the nominal concentration of each standard solution. The
linearity of the method was evaluated by calculating the intercept,
slope, determination coefficient and variation in the range
0.02–5 lg mL1 for ravuconazole, 0.2–5 lg mL1 for terconazole
and 0.05–5lg mL1 for other azole drugs (Tables 1 and 2). The
different curves were linear over the range reported with coeffi-
cients (r2) 0.9846 and weighing factor of (1/x2), which are accord-
ing to International Guidelines36. The calibration curve parameters
are reported in Table 1 for plasma sample and in Table 2 for urine
sample. The LOQ values were 0.02lg mL1 for ravuconazole,
0.2lg mL1 for terconazole and 0.05lg mL1 for other azole
drugs. The LOD values were 0.007 lg mL1 for ravuconazole,
0.07lg mL1 for terconazole and 0.017 lg mL1 for other azole
drugs (Tables 1 and 2). The resulting values were calculated at a
signal-to-noise ratio (3:1).
The within-assay precision (repeatability) of the same day was
carried out by performing six consecutive analyses of QC samples
spiked at three different drug concentrations, e.g. 0.4 (low level),
1.0 (medium level) and 4.0 (high level) lg mL1, which are within
the calibration curve. The QC samples were also analyzed in differ-
ent days to evaluate the between-assay precision (intermediate
precision). The trueness was tested using the same QC concentra-
tions and comparing the back-calculated concentrations with their
nominal values. The intra- and inter-day precision (RSD%) values
were 13.4% and 13.1%, respectively. The intra- and inter-day
trueness (Bias%) values were between 13.4% and 12.4%
(Supplementary material, Section S3, Table S3.1 for plasma and
Table S3.2 for urine). These values strictly respect the limits set
requested by the International Guidelines37, even if are good and
comparable with general analytical procedures, they could be
improved by taking to on-line MEPS systems, in order to further
standardize the extraction process and certainly improve the
reproducibility between samples.
The QCs over 50 lg mL1 were also analyzed by MEPS-HPLC-
DAD after a dilution (50 folds, v:v) with the corresponding blank
matrix. The precision and trueness QC values were comparable
with those obtained for low, medium and high drug concentra-
tions. Moreover, the intra-matrix variability was assessed by analyz-
ing different batches of plasma or urine and no interferences were
observed. No noteworthy changes of drugs concentrations were
observed for stock solutions, working solutions and spiked sam-
ples. The spiked samples stored at 20 C, at þ4 C, and freezing-
thawed samples (n¼ 3 cycles) were stable for at least 1month
(Supplementary material, Section S4 for long-term stability,
Table S4.1 for plasma and Table S4.2 for urine), as previously
reported15,25,39.
The parallelism test was performed using high drug concentra-
tions diluted 50-folds (v:v) with the corresponding blank matrix.
Data showed that an upper limit of quantification could be
accepted for different samples until 50 lg mL1 and above the
maximum value of linearity range reported without decreasing the
analytical parameters.
Comparisons with existing methods
The reported method showed several advantages to analyze sim-
ultaneously 12 azole drugs in terms of time-consuming, simplicity
and routinary instrumentation, analytical performances, applica-
tions in clinic and pharmaceutical fields. Additionally, it shows
comparable performances with respect to FPSE-HPLC-PDA proced-
ure reported in the literature40. This method also improved the
detection and quantification limits for azole drugs in biological
samples. Published data showed that few azoles (only up to five
drugs) can be simultaneously quantified in biological samples
using a single analytical procedure (Table 3). Indeed, different pro-
tocols used complex and highly hyphenated configurations23,41,
which require time and solvent consuming for the samples extrac-
tion12,27,29 and to obtain low level of LOQs. Other procedures
showed that few azoles drugs can be simultaneously analyzed using
methods previously reported; but only one protocol29 showed the
simultaneous analysis of six azoles in cosmetic formulations with a
total running time of 80min and LOQ values similar to those
obtained in this study with only 36min of analysis (Table 3).
The LOQ values, which were carried out using MEPS-HPLC-DAD
procedure, were similar to those obtained using more sensitive
Figure 4. Effects of cycles number on process efficiency for the different analytes during sample loading and sample elution. Values are reported as percentage of
observed analyte area respect to a water-based sample spiked at the same concentration level and submitted to the same extraction procedure.
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Table 3. Comparison of published analytical methods for the analysis of azoles extracted from different biological samples.
Sample Analytes Extraction
Instrument
setting up
Stationary
phase
Total extraction
procedure time
(minutes)
Chromatographic
analysis
(minutes)
LOQ
(lg mL1)
Linear dynamic
range
(lg mL1) Ref.
Serum Posaconazole Column
switching
HPLC-FLD C18 3 17 0.1 0.1–5
13
Plasma/saliva Voriconazole LLE HPLC-FLD C18 6 12 0.1 0.1–10
12
Plasma Itraconazole/metabolite LLE HPLC-FLD C18 25 30 0.005 0.005–0.5
11
Plasma Itraconazole Protein pre-
cipitation
HPLC-UV/Vis C18 10 – 0.08 –
14
Plasma Voriconazole LLE HPLC-UV/Vis C18 15, plus dryness 20 0.1 0.1–20
15
Posaconazole 0.05 0.05–10
Plasma Posaconazole – HPLC-PDA C8 – 65 – –
16
Plasma Itraconazole Protein pre-
cipitation
HPLC-MS/MS C18 – – 0.001 0.001–0.5
20
Plasma Voriconazole LLE HPLC-MS/MS C18 12 – 0.027 –
21
Plasma Posaconazole LLE HPLC-MS/MS C18 – – 0.001 –
22
Interlaboratory
Test
Itraconazole – – – – – – – 23
Voriconazole
Posaconazole
Fluconazole
Formulation Itraconazole – HPLC-UV/Vis Sb-Aq 10 – – – 24
Formulation Voriconazole – HPLC-UV/Vis C18 – 20 – –
25
Related impurities
Ophtalmic Voriconazole – HPLC-UV/Vis C18 – – – –
26
Plasma Voriconazole LLE HPLC-UV/Vis C8 25, plus dryness 20 0.2 0.2–10
27
Posaconazole 0.05 0.05–10
Plasma Fluconazole SPE HPLC-UV/Vis C6-phenyl – 19 0.05 0.05–50
30
Posaconazole 0.05–40
Voriconazole 0.05–40
Itraconazole/metabolite 0.05–40
Cosmetic Ketoconazole Ultrasound
and
Liquid
Extraction
HPLC-UV/Vis RP amide C16 10, plus
centrifugation
80 0.05 0.05–100 28
Tioconazole
Econazole
Miconazole
Itraconazole
Clotrimazole
Plasma Itraconazole Protein pre-
cipitation
HPLC-MS C18 10 13 0.03 0.03–8
19
Voriconazole 0.03 0.03–8
Posaconazole 0.04 0.04–10
Plasma Itraconazole Protein pre-
cipitation
HPLC-UV/Vis C6-phenyl 5 17 0.05 0.05–10
17
Voriconazole
Posaconazole
Rat plasma Itraconazole LLE HPLC-DAD C18 12, plus dryness – 0.05 0.05–5
18
Posaconazole
Plasma Posaconazole Protein pre-
cipitation
HPLC-MS/MS C18 and PFP 10 4 0.1 0.1–20
42
Voriconazole
Itraconazole/metabolite
Plasma Voriconazole LLE UPLC-UV/Vis BEH Phenyl 10, plus dryness 6 0.05 0.05–10 43
Posaconazole
Isavuconazole
Itraconazole/metabolite
Plasma Itraconazole SLE UHPLC-MS/MS Kinetex F5 (PFP) 34 7.6 0.005 0.005–2.5 39
Hydroxy itraconazole
Keto itraconazole
N-Desalkyl itraconazole
Serum Voriconazole Protein pre-
cipitation
UFLC-MS/MS Kinetex C18 6 4 0.1 0.1–10
44
Plasma/urine Ketoconazole MEPS HPLC-DAD C18 7 36 0.05 0.05–5 Current paper
Terconazole 0.2 0.2–5
Voriconazole 0.05 0.05–5
Bifonazole 0.05 0.05–5
Clotrimazole 0.05 0.05–5
Tioconazole 0.05 0.05–5
Econazole 0.05 0.05–5
Butoconazole 0.05 0.05–5
Miconazole 0.05 0.05–5
Posaconazole 0.05 0.05–5
Ravuconazole 0.02 0.02–5
Itraconazole 0.05 0.05–5
PFP: pentafluorophenyl; RP: reversed phase; LLE: liquid–liquid extraction; SLE: solid-supported liquid extraction; plus dryness: required time for complete solvent evap-
oration is not reported; plus centrifugation: required time for sample centrifugation is not reported.
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and selective detectors, e.g. FLD11 or very expensive MS and MS/
MS19,21,42. In many cases, the LOQs of MEPS-HPLC-DAD procedure
showed better values (two-folds) than published data, which were
obtained using few drugs12,13,15,27. The use of benzyl-4-hydroxy-
benzoate as IS allowed monitoring the efficacy of the extraction
and the analytical procedure.
As reported in Table 3, to analyze, a pharmaceutical formula-
tion is necessary to validate a large linear dynamic range (e.g.
from 0.05 to 100 lg mL1)29, while this necessity is not mandatory
when biological matrices are considered. In fact, the availability of
a large dynamic range could help in reducing the number of over-
range samples that need to be re-analyzed.
For azoles herein considered, the biological levels generally
observed are close from low lg mL1 to medium ng mL1
range17–19 for plasma, while for urine, it is necessary to validate
low ng mL1 range due to the low percentage of unchanged ana-
lyte. For this reason, the use of large dynamic range is not neces-
sary as well as the availability of a high sensitivity in biological
matrix analyses. Additionally, the use of large range could affect
the method accuracy (precision and trueness) at low concentration
levels.
Application to real plasma and urine samples
The performances of analytical method were tested in plasma and
urine samples collected from healthy volunteers after single oral
administration of commercial capsules of itraconazole (100mg)
and tablets of micozanole (500mg). Biological samples were
extracted by MEPS device and quantified using HPLC-DAD accord-
ing to the reported validated method. Table 4 reports the quanti-
tative data obtained after real samples analyses (Supplementary
material, Section S5 for real samples chromatograms).
A low concentration of itraconazole was obtained in plasma
after 4 h. This value agreed with data previously reported by
Hardin et al.45, which reported an itraconazole concentration of
0.244± 0.090 lg mL1 at 4 h for a single dose of 2 100mg/die
per os. The low concentration of itraconazole in the urine
suggested that this drug was excreted as non-active metabolites
in urine (35%) and faeces (54%)46.
The plasma concentration of miconazole partially agreed with
previously reported data46 for a single dose of 2 500mg/die per
os. In fact, a low amount of this analyte (<1%) was excreted
unchanged in the urine; while 10–20% of this drug was metabo-
lized before excretion47. The residual unmodified drug (50%)
could be eliminated through faeces48.
Conclusions
The MEPS-HPLC-DAD procedure represents a suitable method to
analyze simultaneously 12 azole drugs in plasma and urine sam-
ples collected from healthy volunteers. The analytical method was
optimized using different columns and mobile phase compositions
to have a short run time, which can separate several antifungal
drugs and benzyl-4-hydroxybenzoate (IS). The best performance of
the analytical method was carried out by using a Luna C18 column,
a binary solvent system made from phosphate buffer (40mM, pH
2.5) and AcN (58:42, v:v), and a flow rate of 1.0mL min1. The gra-
dient elution allows separating 12 azole drugs better than isco-
cratic condition. The performance of MEPS-HPLC-DAD apparatus
also depends on pH, ionic strength of the buffer, temperature of
the column and solvents. Acid pH (2.5), 40mM (ionic strength),
25 C and acetonitrile (solvent elution) provided the best set-up to
separate and analyze azole drugs by using a single run of 36min.
The validation parameters showed that our experimental proto-
col can be used to detect and quantitate simultaneously bifona-
zole, butoconazole, clotrimazole, econazole, itraconazole,
ketoconazole, miconazole, posaconazole, ravuconazole, tercona-
zole, tioconazole, voriconazole in plasma and urine samples col-
lected from healthy volunteers. Samples from human healthy
volunteers after a single oral dose of commercial capsules of itra-
conazole (100mg) and tablets of miconazole (500mg) demon-
strated that the selected azole drugs can be analyzed in real
biological samples (plasma and urine) and showed analytical
parameters similar to standard azole drugs, which are used to
develop and validate the method.
Table 4. Quantitative analysis of plasma or urine samples collected from healthy human volunteers after single oral dose of commercial capsules of itraconazole
(100mg) and commercial tablets of miconazole (500mg). Plasma was collected 4 h after the oral administration of drugs, while urine samples were collected at differ-
ent times.
Itraconazolec Miconazolec
Matrix Sample no. Formulation Dose (mg 2/die) Time (h)a Volume (mL)
Concentration
(lg mL1)
Total amount
(mg)
Concentration
(lg mL1)
Total amount
(mg)
Plasma 1 Capsules 100 4 4400b 0.124 (±0.07) 0.546 n.d. n.d.
2 Tablets 500 4 4400b n.d. n.d. 0.508 (±0.05) 2.235
Urine 3 Capsules 100 0 100d n.d. n.d. n.d. n.d.
4 Capsules 100 3 110d n.d. n.d. n.d. n.d.
5 Capsules 100 6 100d n.d. n.d. n.d. n.d.
6 Capsules 100 9 110d n.d. n.d. n.d. n.d.
7 Capsules 100 12 110d n.d. n.d. n.d. n.d.
8 Capsules 100 18 110d 0.402 (±0.09) 0.044 n.d. n.d.
9 Capsules 100 24 110d n.d. n.d. n.d. n.d.
10 Capsules 100 36 110d n.d. n.d. n.d. n.d.
11 Tablets 500 0 80d n.d. n.d. n.d. n.d.
12 Tablets 500 3 380d n.d. n.d. n.d. n.d.
13 Tablets 500 6 140d n.d. n.d. 0.136 (±0.08) 0.019
14 Tablets 500 9 160d n.d. n.d. 0.229 (±0.04) 0.037
15 Tablets 500 12 120d n.d. n.d. 0.102 (±0.07) 0.012
16 Tablets 500 21 420d n.d. n.d. 0.098 (±0.06) 0.041
17 Tablets 500 24 40d n.d. n.d. 0.048 (±0.03) 0.002
18 Tablets 500 36 60d n.d. n.d. n.d. n.d.
aTime between the last drug administration and sample collection.
bAccording to39.
cIn round brackets are reported standard errors of the mean (SEM) obtained from three independent measures.
dUrine volumes collected from treated patients. n.d.: not detected.
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No interferences were observed between drugs and biological
samples during the validation of method and the analysis of real
samples. The MEPS-HPLC-DAD is an easy and quick procedure,
which can decrease significantly the variability and the time of the
analysis. The MEPS-HPLC-DAD apparatus can provide several
advantages for the simultaneous analysis of antifungal drugs in
multiple therapy and pharmaceutical science. The MEPS-HPLC-DAD
in off-line mode can represent an easy and quick analytical tool to
separate and analyze several drugs in biological samples without
using expensive apparatus and complex methods, which needed
skilled operators.
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